The global ophthalmic drug CDMO market size was valued at USD 1.41 billion in 2025 and is projected to grow from USD 1.52 billion in 2026 to USD 2.83 billion by 2034, registering a CAGR of 8.03% during the forecast period (2026–2034). North America dominated the ophthalmic drug CDMO market with a market share of 39.16% in 2025.
The market includes contract development and manufacturing organizations that provide formulation, development, manufacturing, packaging, and regulatory support for ophthalmic drugs and therapies. They support sterile formulations, eye drops, ointments, injectables, and sustained-release ocular drug delivery products across clinical and commercial stages.
The ophthalmic drug CDMO market demand is driven by the rising prevalence of eye diseases, growing outsourcing by pharmaceutical companies, and increasing demand for specialized manufacturing. Investments in advanced technologies, regulatory expertise, expanding biologics pipelines, and production capabilities are supporting ophthalmic drug CDMO market growth.
Download a Free Sample To learn more about this report,
The ophthalmic drug CDMO market is highly exposed to supply chain disruptions due to its dependence on sterile raw materials, active pharmaceutical ingredients, specialized packaging components, and stringent cold-chain logistics. Disruptions in global sourcing, transportation delays, and shortages of pharmaceutical-grade materials have increased manufacturing lead times and production costs, affecting the timely delivery of ophthalmic products. The market is experiencing a capacity-constrained recovery, driven by expanding production capacity, localized sourcing strategies, and continued investments in resilient supply chain infrastructure to meet growing global demand.
Expansion of Sterile Fill-Finish Capabilities for Complex Ophthalmic Therapies
The growing pipeline of biologics, sustained-release implants, and gene therapies is driving CDMOs to expand specialized sterile fill-finish manufacturing for ophthalmic products. This transition is enabling pharmaceutical companies to outsource complex production while ensuring regulatory compliance and product quality. As a result, manufacturers are increasing investments in aseptic processing, high-containment facilities, and advanced quality systems to support next-generation eye treatments.
Increasing Adoption of Digital Manufacturing and Continuous Quality Monitoring
Ophthalmic drug manufacturers are increasingly adopting digital manufacturing platforms that enable real-time process monitoring, electronic batch records, and predictive quality management to improve manufacturing efficiency and regulatory compliance. This transition is helping CDMOs reduce manual documentation, minimize batch deviations, and accelerate product release while ensuring consistent quality for sterile ophthalmic formulations. The growing emphasis on data integrity and automated manufacturing is encouraging wider deployment of Manufacturing Execution Systems and electronic batch records across pharmaceutical production facilities.
The ophthalmic drug CDMO market forecasts continued investment activity as pharmaceutical companies expand outsourcing of sterile ophthalmic manufacturing, biologics production, and advanced drug delivery technologies. In 2026, Recipharm announced a multi-million-dollar investment to establish a new Blow-Fill-Seal (BFS) manufacturing line at its sterile development and manufacturing facility. The investment is aimed at expanding commercial-scale aseptic production capacity for ophthalmic, inhalation, and other sterile drug products while supporting increasing customer demand for advanced sterile manufacturing services.
Expanding Pipeline of Biologics & Advanced Ocular Therapies and Rising Prevalence of Age-related Eye Diseases Drives Market
The increasing development of biologics, gene therapies, and sustained-release ophthalmic treatments is driving demand for specialized CDMO services with advanced sterile manufacturing capabilities. These complex therapies require sophisticated process development, aseptic fill-finish, and regulatory expertise beyond the capabilities of many drug developers. As a result, CDMOs are expanding their technical infrastructure and manufacturing capacity to support next-generation ophthalmic products.
The increasing incidence of cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy is driving demand for ophthalmic drugs, creating sustained outsourcing opportunities for CDMOs. An aging population and rising diabetes prevalence are expanding the global patient pool requiring long-term ocular therapies. This is encouraging pharmaceutical companies to accelerate product development and scale manufacturing through specialized CDMO partners.
High Capital Investment and Complex Technology Transfer for Ophthalmic Formulations Restrain Market Expansion
Manufacturing ophthalmic drugs requires significant investment in aseptic production lines, isolator technology, cleanrooms, blow-fill-seal systems, and advanced analytical laboratories. These high infrastructure and maintenance costs create substantial barriers for new entrants and smaller contract manufacturers. Consequently, market expansion remains concentrated among established CDMOs with financial resources to develop and maintain specialized ophthalmic manufacturing facilities.
Transferring ophthalmic formulations from laboratory development to commercial manufacturing is technically challenging because small changes in formulation, sterilization processes, or container-closure systems can affect product stability and performance. These complexities increase development timelines, validation requirements, and production risks during scale-up.
Expansion of Ophthalmic Gene Therapy Manufacturing and Growth of Biosimilar Ophthalmic Drugs Open New Revenue Opportunities
The growing pipeline of gene therapies for inherited retinal diseases and other ocular disorders is creating significant opportunities for ophthalmic CDMOs with viral vector development and sterile manufacturing capabilities. Pharmaceutical and biotechnology companies are increasingly seeking specialized partners that can support process development, GMP manufacturing, and commercial-scale production. As more gene therapies advance through late-stage clinical trials and receive regulatory approvals, CDMOs investing in advanced therapy manufacturing are well positioned for long-term growth.
The patent expiry of leading ophthalmic biologics is creating opportunities for CDMOs specializing in biologics process development, analytical testing, and sterile fill-finish manufacturing. Biosimilar developers increasingly rely on contract manufacturing partners to reduce development costs and accelerate regulatory approvals. As more ophthalmic biosimilars enter clinical development and commercialization, CDMOs with expertise in biologics manufacturing and aseptic production are expected to benefit from rising outsourcing demand.
Shortage of Skilled Workforce and Limited Availability of Specialized Raw Materials Challenges Market Growth
Manufacturing ophthalmic drugs requires highly trained personnel with expertise in aseptic processing, sterile quality assurance, microbiological control, and regulatory compliance. The global shortage of experienced biopharmaceutical manufacturing professionals is making it difficult for CDMOs to scale operations and commission new facilities efficiently. This talent gap delays capacity expansion and limits the ability of manufacturers to meet increasing outsourcing demand.
Ophthalmic drug manufacturing depends on high-purity excipients, sterile primary packaging, ophthalmic-grade bottles, droppers, and elastomeric closures that have a limited supplier base. Supply shortages or long procurement lead times can delay production schedules and clinical programs, affecting the ability of CDMOs to deliver projects on time.
Request Customizationto receive a tailored report.
The drug product manufacturing segment accounted for a share of 48.35% in 2025, as high outsourcing of sterile fill-finish operations for ophthalmic eye drops, ointments, and injectables. Commercial batch manufacturing, blow-fill-seal production, and packaging services generated recurring revenues through long-term manufacturing agreements with pharmaceutical companies.
The drug development segment is expected to grow at a CAGR of 8.27% during the forecast period, driven by increasing demand for ophthalmic formulation optimization, preservative-free product development, and ocular bioavailability studies. Rising preformulation, analytical characterization, and process development projects are expanding early-stage outsourcing opportunities.
The small molecules segment is expected to grow at a CAGR of 8.31% during the forecast period, fueled by continuous demand for generic ophthalmic eye drops and topical anti-infective formulations. High-volume production, formulation reformulation, and lifecycle management projects continue driving outsourced manufacturing requirements.
The large molecules segment is expected to grow at a CAGR of 8.59% during the forecast period, driven by retinal biologics require aseptic cell culture, protein purification, and sterile fill-finish expertise. Increasing development of anti-VEGF biosimilars and novel biologics is accelerating outsourcing to specialized CDMOs.
The commercial manufacturing segment accounted for a share of 56.43% in 2025 due to recurring large-scale production of approved ophthalmic products for global markets. Long-term supply contracts and validated commercial manufacturing lines ensured sustained production volumes and stable revenue generation.
The clinical segment is expected to grow at a CAGR of 8.91% during the forecast period, as ophthalmic biologics and gene therapies require flexible small-batch GMP production for clinical trials. Increasing Phase I–III programs are driving demand for rapid manufacturing and analytical release testing.
The pharmaceutical companies accounted for a share of 61.28% in 2025 due to established brands outsource commercial ophthalmic manufacturing to optimize capacity utilization and regulatory compliance. Large approved product portfolios require continuous sterile manufacturing and lifecycle management support.
The biotechnology companies segment is expected to grow at a CAGR of 9.04% during the forecast period, fueled by increasing development of novel ocular biologics without dedicated manufacturing infrastructure. Dependence on CDMOs for process development, GMP production, and regulatory support is accelerating outsourcing demand.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Strong Biopharmaceutical Outsourcing and Advanced Sterile Manufacturing Infrastructure
The North America ophthalmic drug CDMO market accounted for the largest regional share of 39.16% in 2025, driven by strong presence of global pharmaceutical and biotechnology companies, increasing outsourcing of ophthalmic drug development, and well-established sterile manufacturing infrastructure. The region benefits from advanced regulatory frameworks, high R&D spending, and continuous innovation in biologics and gene therapies for eye diseases.
The US ophthalmic drug CDMO market was valued at USD 481.81 million in 2025, driven by increasing outsourcing of sterile ophthalmic manufacturing, expanding pipelines of biologics and retinal therapies, and growing investment in advanced aseptic production facilities. Pharmaceutical and biotechnology companies increasingly rely on CDMOs to accelerate development timelines while meeting stringent regulatory requirements. According to the US FDA, the agency approved 65 novel drugs in 2025, reflecting robust pharmaceutical innovation that continues to support demand for specialized ophthalmic CDMO services.
The Canada ophthalmic drug CDMO market size was valued at USD 71.36 million in 2025, supported by growing pharmaceutical research activities, increasing clinical development of ophthalmic therapies, and expanding investments in biologics manufacturing capabilities. The country's skilled workforce, supportive regulatory environment, and expanding life sciences sector continue to create favorable conditions for ophthalmic CDMO growth.
Asia Pacific: Fastest Growth Driven by Expansion of Local Pharmaceutical Manufacturing and Rising Ophthalmic Clinical Trials
The Asia Pacific ophthalmic drug CDMO market is expected to grow at a CAGR of 9.62% during the forecast period, showcasing the fastest regional growth. Growth is supported by rapid expansion of domestic pharmaceutical manufacturing, increasing ophthalmic clinical trial activity, and growing government support for biopharmaceutical production. Rising investments in contract manufacturing infrastructure and cost-competitive development services are attracting global pharmaceutical companies to the region.
The China ophthalmic drug CDMO market was valued at USD 82.50 million in 2025, supported by expansion of pharmaceutical contract manufacturing clusters, increasing domestic production of ophthalmic biologics and specialty eye-care medicines, and strong government support for high-end biopharmaceutical manufacturing through industrial development zones.
The India ophthalmic drug CDMO market was valued at USD 49.39 million in 2025, fueled by strong manufacturing base for generic ophthalmic formulations, increasing investments in preservative-free and sterile ophthalmic production, and the growing presence of globally compliant USFDA and EU-GMP certified facilities. Rising contract manufacturing for international pharmaceutical companies, expanding exports of ophthalmic medicines, and continuous capacity additions by domestic CDMOs continue to accelerate market growth.
The Japan ophthalmic drug CDMO market was valued at USD 48.99 million in 2025, supported by leadership in innovative ophthalmic drug discovery, strong expertise in retinal disease therapeutics, and increasing demand for high-precision sterile manufacturing. According to Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Japan continues to strengthen expedited pathways for innovative regenerative and ophthalmic therapies, supporting regional CDMO demand.
Unlock Regional Insightsto access country-level data, & regional trends.
The ophthalmic drug CDMO market competitive landscape is moderately consolidated, with competition led by established contract development and manufacturing organizations offering specialized sterile manufacturing, formulation development, analytical testing, and fill-finish services for ophthalmic products. Leading companies compete through advanced aseptic manufacturing capabilities, regulatory expertise, and integrated development services. The ophthalmic drug CDMO market ecosystem is shaped by increasing outsourcing of ophthalmic drug manufacturing, rising demand for biologics and sustained-release therapies, and stringent regulatory standards.
July 2026: Catalent expanded its partnership with Nanoscope Therapeutics to provide late-phase development support, commercial packaging, and distribution for the investigational ophthalmic gene therapy MCO-010.
March 2026: Catalent entered a global collaboration with GelMEDIX to support the development and clinical manufacturing of iPSC-derived cell therapies for ocular and retinal diseases using Catalent's GMP cell therapy platform.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com